Literature DB >> 32470292

Comprehensive Analysis of Genomic Safe Harbors as Target Sites for Stable Expression of the Heterologous Gene in HEK293 Cells.

Seunghyeon Shin1, Su Hyun Kim1, Sung Wook Shin2, Lise Marie Grav3, Lasse Ebdrup Pedersen3, Jae Seong Lee2, Gyun Min Lee1,3.   

Abstract

Human cell lines are being increasingly used as host cells to produce therapeutic glycoproteins, due to their human glycosylation machinery. In an attempt to develop a platform for generating isogenic human cell lines producing therapeutic proteins based on targeted integration, three well-known human genomic safe harbors (GSHs)-AAVS1, CCR5, and human ROSA26 loci-were evaluated with respect to the transgene expression level and stability in human embryonic kidney (HEK293) cells. Among the three GSHs, the AAVS1 locus showed the highest eGFP expression with the highest homogeneity. Transgene expression at the AAVS1 locus was sustained without selection for approximately 3 months. Furthermore, the CMV promoter showed the highest expression, followed by the EF1α, SV40, and TK promoters at the AAVS1 locus. Master cell lines were created using CRISPR/Cas9-mediated integration of the landing pad into the AAVS1 locus and were used for faster generation of recombinant cell lines that produce therapeutic proteins with recombinase-mediated cassette exchange.

Entities:  

Keywords:  CRISPR/Cas9; HEK cells; genomic safe harbor; recombinase-mediated cassette exchange; site-specific integration; therapeutic protein

Mesh:

Substances:

Year:  2020        PMID: 32470292     DOI: 10.1021/acssynbio.0c00097

Source DB:  PubMed          Journal:  ACS Synth Biol        ISSN: 2161-5063            Impact factor:   5.110


  8 in total

Review 1.  Expression of mammalian proteins for diagnostics and therapeutics: a review.

Authors:  Jacqueline Kar Kei Mark; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Mol Biol Rep       Date:  2022-06-08       Impact factor: 2.742

2.  Discovery and validation of human genomic safe harbor sites for gene and cell therapies.

Authors:  Erik Aznauryan; Alexander Yermanos; Elvira Kinzina; Anna Devaux; Edo Kapetanovic; Denitsa Milanova; George M Church; Sai T Reddy
Journal:  Cell Rep Methods       Date:  2022-01-14

3.  Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.

Authors:  André Fedier; Nadia Maggi; Alessandra Tozzi; Muriel Disler; Ricardo Coelho; Francis Jacob; Viola Heinzelmann-Schwarz
Journal:  Int J Oncol       Date:  2022-06-01       Impact factor: 5.884

4.  Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.

Authors:  Shin Yi Tang; Shijun Zha; Zhicheng Du; Jieming Zeng; Detu Zhu; Yumei Luo; Shu Wang
Journal:  Stem Cell Res Ther       Date:  2021-11-21       Impact factor: 6.832

Review 5.  2A and 2A-like Sequences: Distribution in Different Virus Species and Applications in Biotechnology.

Authors:  Juliana G S de Lima; Daniel C F Lanza
Journal:  Viruses       Date:  2021-10-26       Impact factor: 5.048

6.  An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Stem Cells Int       Date:  2022-09-22       Impact factor: 5.131

Review 7.  Recombinant vaccines in 2022: a perspective from the cell factory.

Authors:  Marianna Teixeira de Pinho Favaro; Jan Atienza-Garriga; Carlos Martínez-Torró; Eloi Parladé; Esther Vázquez; José Luis Corchero; Neus Ferrer-Miralles; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2022-10-05       Impact factor: 6.352

8.  Identification of Genomic Safe Harbors in the Anhydrobiotic Cell Line, Pv11.

Authors:  Yugo Miyata; Shoko Tokumoto; Tomohiko Arai; Nurislam Shaikhutdinov; Ruslan Deviatiiarov; Hiroto Fuse; Natalia Gogoleva; Sofya Garushyants; Alexander Cherkasov; Alina Ryabova; Guzel Gazizova; Richard Cornette; Elena Shagimardanova; Oleg Gusev; Takahiro Kikawada
Journal:  Genes (Basel)       Date:  2022-02-24       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.